share_log

Credit Suisse Reiterates Outperform on Jasper Therapeutics, Maintains $4 Price Target

Benzinga ·  Aug 14, 2023 08:08

Credit Suisse analyst Judah Frommer reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment